Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.77 USD | -2.73% | -1.52% | -12.78% |
06-04 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
125B | ||||||
108B | ||||||
24.21B | - | |||||
22.78B | - | |||||
16.43B |